Drugs / WXFL10030390
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03730142 | Oct 2018 → Jul 2020 | — | Shanghai Jiatan Pharmatech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WXFL10030390 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03730142 ↗ |
| Action | Inhibit | “inhibits phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR)” NCT03730142 ↗ |
| Modality | Small molecule | “novel oral small molecular” NCT03730142 ↗ |
| Route | Oral | “WXFL10030390 continuous oral dosing” NCT03730142 ↗ |